This book provides a comprehensive overview of the fast-evolving subject of clinical application of cancer therapeutic biomarkers. The second edition captures significant progress of cancer immunotherapy and emphasizes the genetic basis for selective cancer treatment. It covers an in-depth insight on biomarkers across a broad area of cancer research and oncology with a wealth of integrated genetic and molecular information about specific therapies by a multidisciplinary team of internationally recognized experts. Each chapter focuses on a class of targeted, immunologic, or chemotherapy agents and their companion biomarkers that predict response, benefit or resistance, and severe adverse event. The book will serve as a handbook for health professionals and scientists and will also be useful for patients and general readers interested in the current applicable biomarkers in the management of cancer. The vision into the systemic classification and statistical consideration of therapeutic biomarkers summarized by the book editors and chapter authors will help advance precision medicine—a precisely tailored cancer treatment strategy for cancer patient care.
- TAILORx is a landmark biomarker clinical trial for therapeutic decision of which patients should be recommended for endocrine therapy alone after surgery in node-negative, hormone receptor–positive breast cancer using the Oncotype recurrence scores. Drs. Joseph A. Sparano and Della Makower, principal investigator and investigator of the TAILORx study team, respectively, highlight the monumental achievement (level 1 evidence) of the therapeutic biomarker research and lay down future perspectives of multigene signatures for predicting treatment benefit.
- The second edition also features a contribution from Dr. Nancy Davidson, MD, an international leader in estrogen receptor research and a renowned breast cancer oncologist, and past president of the American Association of Cancer Research and the American Society of Clinical Oncology.
- The book also captures new developments of the immune checkpoint inhibitor therapy and their therapeutic biomarkers for cancer treatment, and increasing number of agents that target the genetic and molecular abnormalities.